Hangzhou Tigermed Consulting Co. Ltd
Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People's Republic of China and internationally. It operates through Clinical Trial Solutions; and Clinical-related and Laboratory Services segments. The company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and to… Read more
Market Cap & Net Worth: Hangzhou Tigermed Consulting Co. Ltd (HNGZY)
Hangzhou Tigermed Consulting Co. Ltd (PINK:HNGZY) has a market capitalization of $492.50 Million ($492.50 Million) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #4335 globally and #2726 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hangzhou Tigermed Consulting Co. Ltd's stock price $4.00 by its total outstanding shares 123124800 (123.12 Million).
Hangzhou Tigermed Consulting Co. Ltd Market Cap History: 2022 to 2025
Hangzhou Tigermed Consulting Co. Ltd's market capitalization history from 2022 to 2025. Data shows change from $1.37 Billion to $492.50 Million (-33.88% CAGR).
Hangzhou Tigermed Consulting Co. Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hangzhou Tigermed Consulting Co. Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.08x
Hangzhou Tigermed Consulting Co. Ltd's market cap is 0.08 times its annual revenue
0.69x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
1.26x
Hangzhou Tigermed Consulting Co. Ltd's market cap is 1.26 times its annual earnings
363.13x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $1.37 Billion | $7.09 Billion | $2.01 Billion | 0.19x | 0.69x |
| 2023 | $507.30 Million | $7.38 Billion | $2.02 Billion | 0.07x | 0.25x |
| 2024 | $509.74 Million | $6.60 Billion | $405.14 Million | 0.08x | 1.26x |
Competitor Companies of HNGZY by Market Capitalization
Companies near Hangzhou Tigermed Consulting Co. Ltd in the global market cap rankings as of March 19, 2026.
Key companies related to Hangzhou Tigermed Consulting Co. Ltd by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #90 globally with a market cap of $177.20 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #151 globally with a market cap of $122.79 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #466 globally with a market cap of $46.38 Billion USD.
- Lonza Group Ltd (PINK:LZAGF): Ranked #511 globally with a market cap of $41.73 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #90 | Thermo Fisher Scientific Inc | NYSE:TMO | $177.20 Billion | $472.71 |
| #151 | Danaher Corporation | NYSE:DHR | $122.79 Billion | $195.21 |
| #466 | IDEXX Laboratories Inc | NASDAQ:IDXX | $46.38 Billion | $586.98 |
| #511 | Lonza Group Ltd | PINK:LZAGF | $41.73 Billion | $596.13 |
Hangzhou Tigermed Consulting Co. Ltd Historical Marketcap From 2022 to 2025
Between 2022 and today, Hangzhou Tigermed Consulting Co. Ltd's market cap moved from $1.37 Billion to $ 492.50 Million, with a yearly change of -33.88%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $492.50 Million | -3.38% |
| 2024 | $509.74 Million | +0.48% |
| 2023 | $507.30 Million | -63.11% |
| 2022 | $1.37 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Hangzhou Tigermed Consulting Co. Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $492.50 Million USD |
| MoneyControl | $492.50 Million USD |
| MarketWatch | $492.50 Million USD |
| marketcap.company | $492.50 Million USD |
| Reuters | $492.50 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.